地西他滨用于治疗恶性血液肿瘤的临床价值分析  

Analysis of clinical value of decitabine in the treatment of hematological malignancies

作　　者：姚铠涛[1] 陈江声[1] 陈春莉[1] 

机构地区：[1]汕头大学医学院第二附属医院,515041

出　　处：《中国实用医药》2015年第22期33-34,共2页China Practical Medicine

摘　　要：目的分析地西他滨用于治疗恶性血液肿瘤的临床价值。方法 110例恶性血液肿瘤患者作为研究对象,随机分为观察组和对照组,每组55例。其中观察组患者采用地西他滨治疗,对照组患者采用吉西他滨治疗,观察两组的临床疗效和不良反应。结果观察组治疗总有效率45.5%明显优于对照组21.8%;观察组不良反应发生率45.5%明显低于对照组70.9%,差异具有统计学意义(P<0.05)。结论地西他滨治疗恶性血液肿瘤疾病具有显著疗效,不良反应发生率低,具有积极的临床推广价值。Objective To analyze clinical value of decitabine in the treatment of hematological malignancies. Methods A total of 110 hematological malignancies patients as study subjects were randomly divided into observation group and control group, with 55 cases in each group. The observation group received decitabine for treatment, and the control group received gemcitabine. Clinical effects and adverse reactions of the two groups were observed. Results The observation group had much better total effective rate as 45.5% than 21.8% of the control group, and its incidence of adverse reactions was obviously lower as 45.5% than 70.9% of the control group. Their differences had statistical significance（P〈0.05）. Conclusion Decitabine provides precise effect in treating hematological malignancies, along with low incidence of adverse reactions. It contains positive value for clinical promotion.

关 键 词：地西他滨 恶性血液肿瘤 吉西他滨 

分 类 号：R733[医药卫生—肿瘤]